Ruxolitinib Therapy Appears Safe Prior to Allogeneic HSCT for Myelofibrosis

The results from a phase II prospective study of patients with primary or secondary myelofibrosis receiving ruxolitinib and then hematopoietic stem cell transplant could help define the optimal time between the two therapies to achieve the best outcome and avoid complications.


By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.